1. Adverse events using shorter MDR-TB regimens: outcomes from Port Moresby, Papua New Guinea
- Author
-
N. Akai, C. Y. Mason, T. Marquardt, A. Prieto, H. Bogati, and L. Sannino
- Subjects
medicine.medical_specialty ,business.industry ,Health Policy ,Public Health, Environmental and Occupational Health ,New guinea ,Disease ,medicine.disease ,03 medical and health sciences ,Regimen ,0302 clinical medicine ,Port (medical) ,030228 respiratory system ,Ototoxicity ,Internal medicine ,Cohort ,medicine ,030212 general & internal medicine ,Adverse effect ,business ,Notes from the Field - Abstract
Evidence increasingly indicates that standardised, shorter regimens (SR) for multidrug-resistant TB (MDR-TB) is effective in treating this global disease, but there is little published data on associated adverse events. We report outcomes from a cohort treated with the SR in Port Moresby, Papua New Guinea (PNG). Among 26 patients treated with a TB SR from September 2017 to September 2018, 10 (39%) were successful treatments, 12 (46%) were failures, 2 died, and 2 were lost to follow-up. Of those whose treatment failed, most (Les preuves disponibles montrent de plus en plus que des protocoles standardisés, plus courts (SR) de la TB multirésistante (MDR-TB) traitent efficacement cette maladie mondiale, mais il y a peu de données publiées sur les effets secondaires. Nous rapportons les résultats d’une cohorte traitée par SR à Port Moresby, Papouasie Nouvelle-Guinée (PNG). Parmi 26 patients traités par SR de TB de septembre 2017 à septembre 2018 : 10 (39%) ont été traités avec succès, 12 (46%) ont échoué, 2 sont décédés et 2 ont été perdus de vue. Parmi les échecs, la majorité (
- Published
- 2021